Ventas
VTR NYSE· Health Care REITs
Last close · Oct 27, 2026
$83.34
KIRA · Stoqly’s AI analyst, in plain words
- Ventas had $5.8B of revenue in fiscal 2025, up 18.5% on the year before. Over five years, revenue changed +9.0% a year on average.
- Ventas made $262M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew −12.8% a year.
- Ventas returned $860M to shareholders in fiscal 2025. The diluted share count rose 11.1%.
- Ventas owes $12.3B more than it holds in cash, about 5.6 years of operating profit.
Market cap
$41.5B
P/E
157.2x
Revenue
$5.8B
Net income
$262M
Free cash flow
—
Operating margin
—
Ventas in 30 seconds · fiscal 2025
Are sales growing?
+18.5%
Yes. Sales grew 18.5% last year.
Does it make a profit?
4.5%
A little. It keeps 4.5% of every sale as profit.
Is debt under control?
5.6x
Heavy. Repaying its debt would take 5.6 years of operating profit.
How is the share priced?
157.2x
One share costs 157.2 times its yearly profit per share. Typical for its sector: 27.8x.
What Ventas does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 6, 2026
- Legal name
- Ventas, Inc.
- CIK
- 0000740260
Ventas · VTR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $3.8B | $4.1B | $4.5B | $4.9B | $5.8B |
| Revenue growth | 0.9% | 7.9% | 8.9% | 9.5% | 18.5% |
| Net income | $56.6M | −$40.9M | −$30.3M | $88.4M | $262M |
| Net margin | 1.5% | −1.0% | −0.7% | 1.8% | 4.5% |
| Diluted EPS | $0.13 | −$0.12 | −$0.10 | $0.19 | $0.54 |
| Cash | |||||
| Cash from operations | $1.0B | $1.1B | $1.1B | $1.3B | $1.6B |
| Dividends paid | $687M | $720M | $724M | $740M | $860M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 2.6% | 4.4% | 0.6% | 2.6% | 11.1% |
| Debt and strength | |||||
| Cash and short-term investments | $150M | $123M | $509M | $898M | $741M |
| Debt incl. finance leases | $12.0B | $12.3B | $13.5B | $13.5B | $13.0B |
| Shareholders' equity | $10.9B | $10.2B | $9.5B | $10.8B | $12.5B |
| Net debt / EBITDA | 8.1x | 7.8x | 7.0x | 6.8x | 5.6x |
| Interest coverage | 0.6x | 0.8x | 0.8x | 1.0x | 1.3x |
| Returns and quality | |||||
| Return on capital | 1.0% | 1.3% | 1.6% | 2.0% | 3.4% |
| Return on equity | 0.5% | −0.4% | −0.3% | 0.9% | 2.2% |
Insiders bought, 12 months
$0.2M
1 insider
Insiders sold, 12 months
$42.7M
5 insiders
Of sales under plans
93%
$39.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Ventas · VTR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Ventas VTR | $41.5B | 18.5% | — | — | 3.4% | 157.2x | — |
| Welltower WELL | $164.7B | 35.6% | — | — | 3.0% | 112.8x | — |
| Healthpeak Properties DOC | $13.1B | 4.5% | — | 12.7% | 3.2% | 54.3x | — |
| American Healthcare REIT AHR | $9.9B | 9.2% | 18.4% | — | — | 75.1x | — |
| Omega Healthcare Investors OHI | $14.6B | 13.2% | — | 67.0% | 8.8% | 16.5x | — |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $83.34 a share, the company is worth $41.5B: 157.2 times its earnings of the last four quarters.
Ventas grew sales faster than 3 of its 4 similar companies. Its P/E is higher than 4 of 4.
Source: SEC EDGAR XBRL filings (CIK 0000740260). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.